- Home
- APTO
as 11-15-2024 4:00pm EST
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
| Founded: | 1986 | Country: | Canada |
| Employees: | N/A | City: | TORONTO |
| Market Cap: | 7.2M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 70.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $2.91 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aptose Biosciences Inc. News
APTO Breaking Stock News: Dive into APTO Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Aptose Reports Results for the Third Quarter 2024
GlobeNewswire
2 months ago
Aptose Announces Results from Special Meeting of Shareholders
MT Newswires
2 months ago
Top Premarket Gainers
Pharmaceutical Technology
3 months ago
Aptose Biosciences secures funds for AML treatment development
MT Newswires
3 months ago
Aptose Biosciences Up 65% In US After Hours As Gets US$10 Million Loan From Hanmi Pharmaceutical
GlobeNewswire
3 months ago
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
GlobeNewswire
3 months ago
Aptose Announces Adjournment of its Special Meeting of Shareholders
Associated Press Finance
3 months ago
Aptose Biosciences: Q2 Earnings Snapshot
Compare APTO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APTO Aptose Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.